The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat

Developmental Brain Research

Volumn 142, Issue 2, 2003, Pages 209-213

  Zhu, Hongbo ^a   Jenab, Shirzad ^a,b   Jones, Kathy L ^a   Inturrisi, Charles E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

c fos mRNA; Dextromethorphan; Morphine withdrawal; NMDA receptor antagonist

Indexed keywords

DEXTROMETHORPHAN; MESSENGER RNA; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN C FOS;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; DRUG WITHDRAWAL; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

EID: 0037616431     PISSN: 01653806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-3806(03)00059-2     Document Type: Article

References (37)

1. Alemzadeh R., Gammeltoft K., Matteson K. Efficacy of low-dose dextromethorphan in the treatment of non-ketotic hyperglycinemia. Pediatrics. 97:1996;924-926.
2. Barr G.A. Behavioral effects of opiates during development. Miller M.W. Development of the Central Nervous System: Effects of Alcohol and Opiates. 1992;221-254 Wiley-Liss, New York.
3. Bem J.L., Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 7:1992;190-199.
4. Bisaga A., Gianelli P., Popik P. Opiate withdrawal with dextromethorphan. Am. J. Psychiatry. 154:1997;584.
5. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl.). 157:2001;1-10.
6. Curran T., Gordon M.B., Rubino K.L., Sambucetti L.C. Isolation and characterization of the c-fos (rat) cDNA and analysis of post-translational modification in vitro. Oncogene. 2:1987;79-84.
7. Geller L.M., Geller E.H. A simple technique for the permanent marking of newborn albino rats. Psychol. Rep. 18:1966;221-222.
8. Hutchings D.E., Dow-Edwards D. Animal models of opiate, cocaine, and cannabis use. Clin. Perinatol. 18:1991;1-22.
9. Inturrisi C.E. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence. Semin. Neurosci. 9:1997;110-119.
10. Jones K.L., Barr G.A. Ontogeny of morphine withdrawal in the rat. Behav. Neurosci. 109:1995;1189-1198.
11. Jones K.L., Zhu H., Jenab S., Du T., Inturrisi C.E., Barr G.A. Attenuation of acute morphine withdrawal in the neonatal rat by the competitive NMDA receptor antagonist LY235959. Neuropsychopharmacology. 26:2002;301-310.
12. Koyuncuoglu H. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int. J. Clin. Pharmacol. Ther. 33:1995;13-19.
13. Koyuncuoglu H., Saydam B. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int. J. Clin. Pharmacol. Ther. Toxicol. 28:1990;147-152.
14. Lu F.L., Wang P.J., Hwu W.L., Tsou Yau K.I., Wang T.R. Neonatal type of non-ketotic hyperglycinemia. Pediatr. Neurol. 20:1999;295-300.
15. Manning B.H., Mao J., Frenk H., Price D.D., Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 67:1996;79-88.
16. Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res. Brain Res. Rev. 30:1999;289-304.
17. Mao J., Price D.D., Caruso F.S., Mayer D.J. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain. 67:1996;361-368.
18. Mayer D.J., Mao J., Holt J., Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. USA. 96:1999;7731-7736.
19. McLemore G.L., Kest B., Inturrisi C.E. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. Brain Res. 778:1997;120-126.
20. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science. 278:1997;58-63.
21. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53:1996;791-797.
22. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 280:1997;854-865.
23. Popik P., Kozela E., Danysz W. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn Schmiedebergs Arch. Pharmacol. 361:2000;425-432.
24. Purcell-Jones G., Dormon F., Sumner E. The use of opioids in neonates. A retrospective study of 933 cases. Anaesthesia. 42:1987;1316-1320.
25. Rasmussen K., Brodsky M., Inturrisi C.E. NMDA antagonists and clonidine block c-fos expression during morphine withdrawal. Synapse. 20:1995;68-74.
26. Rosen M.I., McMahon T.J., Woods S.W., Pearsall H.R., Kosten T.R. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur. J. Pharmacol. 307:1996;251-257.
27. Sharma S.K., Klee W.A., Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc. Natl. Acad. Sci. USA. 72:1975;3092-3096.
28. Suresh S., Anand K.J. Opioid tolerance in neonates: a state-of-the-art review. Paediatr. Anaesth. 11:2001;511-521.
29. Thornton S.R., Smith F.L. Characterization of neonatal rat fentanyl tolerance and dependence. J. Pharmacol. Exp. Ther. 281:1997;514-521.
30. Thornton S.R., Wang A.F., Smith F.L. Characterization of neonatal rat morphine tolerance and dependence. Eur. J. Pharmacol. 340:1997;161-167.
31. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
32. Yeh G.C., Tao P.L., Chen J.Y., Lai M.C., Gao F.S., Hu C.L. Dextromethorphan attenuates morphine withdrawal syndrome in neonatal rats passively exposed to morphine. Eur. J. Pharmacol. 453:2002;197-202.
33. Zhu H., Barr G.A. Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists. Psychopharmacology (Berl.). 150:2000;325-336.
34. Zhu H., Barr G.A. Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age dependent. Synapse. 40:2001;282-293.
35. Zhu H., Barr G.A. Opiate withdrawal during development: are NMDA receptors indispensable? Trends Pharmacol. Sci. 22:2001;404-408.
36. Zhu Y.S., Brodsky M., Franklin S.O., Huang T., Inturrisi C.E. Metrazole induces the sequential activation of c-fos, proenkephalin, and tyrosine hydroxylase gene expression in the rat adrenal gland: modulation by glucocorticoid and adrenocorticotropic hormone. Mol. Pharmacol. 44:1993;328-335.
37. Zhu Y.S., Branch A.D., Robertson H.D., Huang T.H., Franklin S.O., Inturrisi C.E. Time course of enkephalin mRNA and peptides in cultured rat adrenal medulla. Brain Res. Mol. Brain Res. 12:1992;173-180.